Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 2, Number 3—July 1996
Synopsis

Coccidioidomycosis: A Reemerging Infectious Disease

Theo N. Kirkland and Joshua Fierer
Author affiliations: Author affiliations: Departments of Pathology and Medicine, University of California, San Diego School of Medicine (T.N. Kirkland); Department of Veterans Affairs Medical Center, San Diego, California, USA (J. Fierer)

Main Article

Figure 5

The most common clinical presentations of coccidioidomycosis in AIDS patients. The group "Other" includes dissemination to the lymph nodes, liver, spleen, and bone marrow. The antibody only group includes patients with serologic evidence of infection but no evident focus of infection. Since these were passively collected cases, a protocol to search for inapparent sites of infection had not been agreed upon (37).

Figure 5. The most common clinical presentations of coccidioidomycosis in AIDS patients. The group "Other" includes dissemination to the lymph nodes, liver, spleen, and bone marrow. The antibody only group includes patients with serologic evidence of infection but no evident focus of infection. Since these were passively collected cases, a protocol to search for inapparent sites of infection had not been agreed upon (37).

Main Article

References
  1. Morse  SS. Factors in the emergence of infectious diseases. Emerg Infect Dis. 1995;1:7–15. DOIPubMedGoogle Scholar
  2. Deresinski  SC. History of coccidioidomycosis: “dust to dust.” In: Stevens DA, editor. Coccidioidomycosis. New York: Plenum, 1980:1-20.
  3. Harrison  WR, Merbs  CF, Leathers  CR. Evidence of coccidioidomycosis in the skeleton of an ancient Arizona Indian. J Infect Dis. 1991;164:436–7.PubMedGoogle Scholar
  4. Cole  GT, Sun  SH. Arthroconidium-spherule-endospore transformation in Coccidioides immitis. In: Szaniszlo PJ, Harris L, editors. Fungal dimorphism: with emphasis on fungi pathogenic for humans. New York: Plenum, 1985:281-333.
  5. Pappagianis  D. Epidemiology of coccidioidomycosis. Curr Top Med Mycol. 1988;2:199–238.PubMedGoogle Scholar
  6. Converse  JL. Effect of surface active agents on endosporulation of Coccidioides immitis in a chemically defined medium. J Bacteriol. 1957;74:106–7.PubMedGoogle Scholar
  7. Kamel  SM, Wheat  LJ, Garten  ML, Bartlett  MS, Tansey  MR, Tewari  RP. Production and characterization of murine monoclonal antibodies to Histoplasma capsulatum yeast cell antigens. . Infect Immun. 1989;57:896–901.PubMedGoogle Scholar
  8. Lacy  GH, Swatek  FE. Soil ecology of Coccidioides immitis at Amerindian middens in California. Appl Microbiol. 1974;27:379–88.PubMedGoogle Scholar
  9. Maddy  KT. The geographic distribution of Coccidioides immitis and possible ecologic implications. Ariz Med. 1958;15:178–88.PubMedGoogle Scholar
  10. Smith  CE, Beard  RR, Rosenberger  HG, Whiting  EG. Effect of season and dust control on coccidioidomycosis. JAMA. 1946;132:833–8.
  11. Pappagianis  D, Einstein  H. Tempest from Tehachapi takes toll or Coccidioides conveyed aloft and afar. West J Med. 1978;129:527–30.PubMedGoogle Scholar
  12. CDC. Coccidioidomycosis following the Northridge earthquake—California, 1994. MMWR. 1994;43:194–5.PubMedGoogle Scholar
  13. Johnson  WM. Occupational factors in coccidioidomycosis. J Occup Med. 1981;23:367–74. DOIPubMedGoogle Scholar
  14. Werner  SB, Pappagianis  D. Coccidioidomycosis in northern California—an outbreak among archeology students near Red Bluff. Calif Med. 1973;119:16–20.PubMedGoogle Scholar
  15. Smith  CE, Beard  RR, Whiting  EG, Rosenberg  HG. Varieties of coccidioidal infection in relation to the epidemiology and control of diseases. Am J Public Health. 1946;36:1394–402. DOIGoogle Scholar
  16. Galgiani  JN. Coccidioidomycosis. West J Med. 1993;159:153–71.PubMedGoogle Scholar
  17. Smith  CE. Epidemiology of acute coccidioidomycosis with erythema nodosum (“San Joaquin” or “Valley Fever”). Am J Public Health. 1940;30:600–11. DOIGoogle Scholar
  18. Baker  EJ, Hawkins  JA, Waskow  EA. Surgery for coccidioidomycosis in 52 diabetic patients with special reference to related immunologic factors. J Thorac Cardiovasc Surg. 1978;75:680–7.PubMedGoogle Scholar
  19. Smith  CE, Beard  RR, Saito  MT. Pathogenesis of coccidioidomycosis with special reference to pulmonary cavitation. Ann Intern Med. 1948;29:623–55.PubMedGoogle Scholar
  20. Williams  PL, Sable  DL, Mendez  P, Smyth  LT. Symptomatic coccidioidomycosis following a severe natural dust storm—an outbreak at the Naval Air Station, Lemoore, Calif. Chest. 1979;76:566–70. DOIPubMedGoogle Scholar
  21. Kirkland  TN, Fierer  J. Inbred mouse strains differ in resistance to lethal Coccidiodes immitis infection. Infect Immun. 1983;40:912.PubMedGoogle Scholar
  22. Kirkland  TN, Fierer  J. Genetic control of resistance to Coccidioides immitis: a single gene that is expressed in spleen cells determines resistance. J Immunol. 1985;135:548–52.PubMedGoogle Scholar
  23. Cox  RA, Kennell  W. Suppression of T-lymphocyte response by Coccidioides immitis antigen. Infect Immun. 1988;56:1424–9.PubMedGoogle Scholar
  24. Wack  EE, Ampel  NM, Galgiani  JN, Bronnimann  DA. Coccidioidomycosis during pregnancy—an analysis of ten cases among 47,120 pregnancies. Chest. 1988;94:376–9. DOIPubMedGoogle Scholar
  25. Powell  BL, Drutz  DJ, Huppert  M, Sun  SH. Relationship of progesterone- and estradiol-binding proteins in Coccidioides immitis to coccidioidal dissemination in pregnancy. Infect Immun. 1983;40:478–85.PubMedGoogle Scholar
  26. Wegmann  TG, Lin  H, Guilbert  L, Mosmann  TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today. 1993;14:353–6. DOIPubMedGoogle Scholar
  27. Beaman  L, Pappagianis  D, Benjamini  E. Significance of T-cells in resistance to experimental murine coccidioidomycosis. Infect Immun. 1977;17:580–5.PubMedGoogle Scholar
  28. Einstein  HE, Johnson  RH. Coccidioidomycosis: new aspects of epidemiology and therapy. Clin Infect Dis. 1993;16:349–54.PubMedGoogle Scholar
  29. Jinadu  BA. Valley Fever Task Force report on the control of Coccidioides immitis.Bakersfield, CA: Kern Country Health Department, 1995.
  30. Pappagianis  D. Marked increase in cases of coccidioidomycosis in California: 1991, 1992, and 1993. Clin Infect Dis. 1994;19:S14–8.PubMedGoogle Scholar
  31. CDC. Update: Coccidioidomycosis--California, 1991-1993. MMWR. 1994;43:421–3.PubMedGoogle Scholar
  32. Dodge  RR, Lebowitz  MD, Barbee  R, Burrows  B. Estimates of C. immitis infection by skin test reactivity in an endemic community. Am J Public Health. 1985;75:863–5. DOIPubMedGoogle Scholar
  33. Cohen  IM, Galgiani  JN, Potter  D, Ogden  DA. Coccidioimomycosis in renal replacement therapy. Arch Intern Med. 1982;142:489–94. DOIPubMedGoogle Scholar
  34. Rutala  PJ, Smith  JW. Coccidioidomycosis in potentially compromised hosts: the effect of immunosuppressive therapy in dissemination. Am J Med Sci. 1978;275:283–95. DOIPubMedGoogle Scholar
  35. Krishnan  L, Guilbert  LJ, Russell  AS, Wegmann  TG, Mosmann  TR, Belosevic  M. Pregnancy impairs resistance of C57BL/6 mice to Leishmania major infection and causes decreased antigenspecific IFN-gamma response and increased production of T helper 2 cytokines. J Immunol. 1996;156:644–52.PubMedGoogle Scholar
  36. Bronnimann  DA, Adam  RD, Galgiani  JN, Habib  MP, Peterson  EA, Porter  B, Coccidioidomycosis in the acquired immunodeficiency syndrome. Ann Intern Med. 1987;106:372–9.PubMedGoogle Scholar
  37. Fish  DG, Ampel  NM, Galgiani  JN, Dols  CL, Kelly  PC, Johnson  CH, Coccidioidomycosis during human immunodeficiency virus infection—a review of 77 patients. Medicine (Baltimore). 1990;69:384–91. DOIPubMedGoogle Scholar
  38. Ampel  NM, Dols  CL, Galgiani  JN. Coccidioidomycosis during human immunodeficiency virus infection: results of a prospective study in a coccidioidal endemic area. Am J Med. 1993;94:235–40. DOIPubMedGoogle Scholar
  39. Galgiani  JN, Catanzaro  A, Cloud  GA, Higgs  J, Friedman  BA, Larsen  RA, Fluconazole therapy for coccidioidal meningitis: the NIAID-Mycoses Study Group. Ann Intern Med. 1993;119:28–35.PubMedGoogle Scholar
  40. Tucker  RM, Denning  DW, Dupont  B, Stevens  DA. Itraconazole therapy for chronic coccidioidal meningitis. Ann Intern Med. 1990;112:108–12.PubMedGoogle Scholar
  41. Dewsnup  DH, Galgiani  JN, Leviner  BE, Sharkey-Mathin  PK, Fierer  J, Stevens  DA. Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann Intern Med. 1996;124:305–10.PubMedGoogle Scholar
  42. Catanzaro  A, Fierer  J, Friedman  PJ. Fluconazole in the treatment of persistent coccidioidomycosis. Chest. 1990;97:666–9. DOIPubMedGoogle Scholar
  43. Graybill  JR, Stevens  DA, Galgiani  JN, Dismukes  WE, Cloud  GA, . Itraconazole treatment of coccidioidomycosis. Am J Med. 1990;89:282–90. DOIPubMedGoogle Scholar
  44. Catanzaro  A, Galgiani  JN, Levine  BE, Sharkey-Mathis  PK, Fierer  J, Stevens  DA, Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. NIAID Mycoses Study Group. Am J Med. 1995;98:249–56. DOIPubMedGoogle Scholar
  45. Levine  HB, Cobb  JM, Smith  CE. Immunogenicity of spherule-endospore vaccines of Coccidioides immitis for mice. J Immunol. 1961;87:218–27.PubMedGoogle Scholar
  46. Pappagianis  D, Evaluation of the protective efficacy of the killed Coccidioides immitis spherule vaccine in humans. Am Rev Respir Dis. 1993;148:656–60.PubMedGoogle Scholar
  47. Huppert  M, Spratt  NS, Vukovich  KR, Sun  SH, Rice  EH. Antigenic analysis of coccidioidin and spherulin determined by two-dimensional immunoelectrophoresis. Infect Immun. 1978;20:541–51.PubMedGoogle Scholar
  48. Cox  RA, Britt  LA. Isolation and identification of an exoantigen specific for Coccidioides immitis. Infect Immun. 1986;52:138–43.PubMedGoogle Scholar
  49. Cole  GT, Kirkland  TN, Sun  SH. An immunoreactive, water-soluble conidial wall fraction of Coccidioides immitis. Infect Immun. 1987;55:657–67.PubMedGoogle Scholar
  50. Cole  GT, Kirkland  TN, Zhu  M, Yuan  L, Sun  SH, Hearn  VN. Immunoreactivity of a surface wall fraction produced by spherules of Coccidioides immitis. Infect Immun. 1988;56:2695–701.PubMedGoogle Scholar
  51. Dugger  KO, Galgiani  JN, Ampel  NM, Sun  SH, Magee  DM, Harrison  J, . An immunoreactive apoglycoprotein purified from Coccidioides immitis. . Infect Immun. 1991;59:2245–51.PubMedGoogle Scholar
  52. Galgiani  JN, Sun  SH, Dugger  KO, Ampel  NM, Grace  GC, Harrison  J, An arthroconidial spherule antigen of Coccidioides immitis: differential expression during in vitro fungal development and evidence for humoral response in humans after infection or vaccination. Infect Immun. 1992;60:2627–35.PubMedGoogle Scholar
  53. Kirkland  TN, Zhu  SW, Cruse  D, Hsu  LL, Seshan  KR, Cole  GT. Coccidioides immitis fractions which are antigenic for immune T lymphocytes. Infect Immun. 1991;59:3952–61.PubMedGoogle Scholar
  54. Wycoff  E, Pishco  J, Kirkland  TN, Cole  GT. Cloning and expression of a T-cell reactive protein from Coccidioides immitis: homology to 4-hydroxyphenylpyruvate dixygenase and the mammalian Fantigen. Gene. 1995;161:107–11. DOIPubMedGoogle Scholar
  55. Lecara  G, Cox  RA, Simpson  RB. Coccidioides immitis vaccine: potential of an alkali-soluble, water-soluble cell wall antigen. Infect Immun. 1983;39:473–5.PubMedGoogle Scholar

Main Article

Page created: December 20, 2010
Page updated: December 20, 2010
Page reviewed: December 20, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external